Trial Profile
An Open Label, Single Arm, Multicenter Phase II Study of BYL719 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck Who Failed to Respond to Platinum-based Therapy.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Alpelisib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 15 Jul 2018 Planned number of patients changed from 51 to 43.
- 15 Jul 2018 Planned End Date changed from 1 Mar 2018 to 1 May 2019.
- 15 Jul 2018 Planned primary completion date changed from 1 Sep 2017 to 1 May 2019.